1. ALLA AKTIER
  2. NYHETER
  3. Q-LINEA

Q-Linea

Nyheter Q-Linea Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Q-linea uses an additional 30 MSEK within the framework of previously communicated loan facility from the main owner Nexttobe

Q-linea AB (publ) (OMX: QLINEA) – Q-linea announces today that the company's main owner Nexttobe has granted Q-linea an additional short-term loan of SEK 30 million (total SEK 87 million). This loan is provided within the framework of the previously communicated loan facility (amounting to a total of SEK 200 million). Terms and conditions as approved by Q-linea annual general meeting June 13, 2023.

According to the terms and conditions approved at Q-linea annual general meeting June 13, Nexttobe has the right to a market-wise interest rate for loans granted within the framework of the loan facility. The loans will have a floating interest rate based on reference rate Swestr + 4 percentage units, but not lower than 6%. Loans mature June 30, 2024, and are amortization-free during the term. Q-linea has however the right to amortise any amount during the term.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Attachments

Q-linea uses an additional 30 MSEK within the framework of previously communicated loan facility from the main owner Nexttobe

Datum 2023-06-19, kl 17:17
Källa MFN
Bifogade filer
Q-linea uses an additional 30 MSEK within the framework of previously communicated loan facility from the main owner Nexttobe